Goldman Sachs Initiates Coverage On Arvinas with Buy Rating, Announces Price Target of $157
Goldman Sachs analyst Madhu Kumar initiates coverage on Arvinas (NASDAQ:ARVN) with a Buy rating and announces Price Target of $157.
Pfizer, Arvinas Report PROTAC Protein Degrader ARV-471 Continues To Show Clinical Benefit Rate In Patients With Locally Advanced, Metastatic ER-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
– ARV-471 continues to show a favorable tolerability profile and robust ER degradation in updated phase 1 dose escalation data presented at San Antonio Breast Cancer Symposium –
– ARV-471 is expected
The Daily Biotech Pulse: Lilly Sings Metabolic Disorder Drug Pact, Moderna Reports Positive Flu Vaccine Data, Halozyme To Buy Back Shares
Here's a roundup of top developments in the biotech space over the last 24 hours.
Cowen & Co. Initiates Coverage On Arvinas with Outperform Rating
Cowen & Co. analyst Tyler Van Buren initiates coverage on Arvinas (NASDAQ:ARVN) with a Outperform rating.
Arvinas Q3 EPS $(0.94) Down From $(0.79) YoY, Sales $9.28M Up From $7.60M YoY
Arvinas (NASDAQ:ARVN) reported quarterly losses of $(0.94) per share. This is a 18.99 percent decrease over losses of $(0.79) per share from the same period last year. The company reported $9.28 million in sales this
Analyst Ratings For Arvinas
Arvinas (NASDAQ:ARVN) has observed the following analyst ratings within the last quarter:
SVB Leerink Initiates Coverage On Arvinas with Outperform Rating, Announces Price Target of $115
SVB Leerink analyst Andrew Berens initiates coverage on Arvinas (NASDAQ:ARVN) with a Outperform rating and announces Price Target of $115.